SCHEMBL30809221

SCHEMBL30809221

CSC(=S)OC1(c2nccc(Cl)n2)COC1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31691940 0.90 — —
SCHEMBL31568031 0.83 — —
SCHEMBL31691828 0.78 TAS1R3 (0.30) —
SCHEMBL38654184 0.74 TRPV1 (0.32) —
SCHEMBL31543585 0.73 — —
SCHEMBL26685850 0.70 WDR91 (0.31) —
SCHEMBL21812494 0.68 CTH (0.35) —
SCHEMBL29187117 0.67 KMT2A (0.30) —
SCHEMBL31543492 0.67 — —
SCHEMBL26685227 0.67 — —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250304577-A1 TYK2 INHIBITORS BIOGEN MA INC. 2025-10-02 — — US disclosed
EP-4543544-A1 TYROSINE KINASE 2 INHIBITORS AND USES THEREOF Biogen MA Inc. (US) 2025-04-30 — — EP disclosed
WO-2023250064-A1 TYROSINE KINASE 2 INHIBITORS AND USES THEREOF BIOGEN MA INC. (US) 2023-12-28 — — WO disclosed
Send feedback